Targeting angiogenesis in the microenvironment of a tumor can enable suppression of
tumor angiogenesis and delivery of anticancer drugs into the tumor. Anti-angiogenesis targeted delivery
systems utilizing passive targeting such as Enhanced Permeability and Retention (EPR) and
specific receptor-mediated targeting (active targeting) should result in tumor-specific targeting. One
targeted anti-angiogenesis approach uses peptides conjugated to nanoparticles, which can be loaded
with anticancer agents. Anti-angiogenesis agents can suppress tumor angiogenesis and thereby affect
tumor growth progression (tumor growth arrest), which may be further reduced with the targetdelivered
anticancer agent. This review provides an update of tumor vascular targeting for therapeutic
and diagnostic applications, with conventional or long-circulating nanoparticles decorated with
peptides that target neovascularization (anti-angiogenesis) in the tumor microenvironment.
Keywords: Angiogenesis, anti-angiogenesis, anticancer, chemotherapy, passive targeting, active targeting, peptide,
nanoparticles, cancer therapy, diagnosis.
Rights & PermissionsPrintExport